Arcutis Biotherapeutics (ARQT) said its lead drug, ZORYVE, has already surpassed the company's 2026 goals. The company spoke at the 3rd Annual Guggenheim Healthcare Innovation Conference on Tuesday, 10 November 2026.
Management said ZORYVE generated more than $500 million in annual revenue in 2026. The company raised its full-year guidance twice during the year. The source reports revenue of $508.68 million over the last twelve months, up 60% year over year.
Arcutis said it has been cash flow positive for four consecutive quarters and net income positive in three of the last four quarters. Management sees peak sales potential of $2.5 billion to $3.5 billion for ZORYVE. Chief executive Frank Watanabe said the drug's efficacy, safety, tolerability and convenience have helped it gain traction in chronic skin diseases. He said doctors and patients are moving away from topical steroids because of long-term safety concerns.
Chief commercial officer Rob Lisicki said the company holds a 3.5% share of the branded non-steroidal topical dermatology market. He said dermatologists still prescribe far more topical steroids than branded non-steroidal products.
Arcutis expects several catalysts in 2027. These include a pediatric atopic dermatitis approval, broader sales coverage and a brand campaign with Simone Biles. The company said its lead pipeline asset, ARQ-234, is enrolling in a phase 1 multiple ascending dose study. A proof-of-concept study is expected to begin after phase 1 is complete.